

For personal use only



My Rewards International Limited  
Quarterly Activities Report  
For the Period ended 30 June 2025

**myrewards**

## QUARTERLY ACTIVITIES REPORT FOR THE PERIOD ENDING 30 JUNE 2025

### Leading provider of customised solutions to attract, engage and retain employees & customers.

My Rewards International Limited (MRI, My Rewards, or the Company), a global provider of subscription-based customer engagement technologies, is pleased to present its Quarterly Activities Report for the period ending 30 June 2025.

During the June 2025 quarter, the Company continued to progress on its growth strategy following the acquisition and integration of Fly Wallet Pty Ltd—an AFS-licensed, Mastercard Principal Member. This acquisition significantly enhances MRI's capability to deliver white-labelled, Mastercard-backed loyalty programs and card linked reward programs for B2B and B2C clients.

The Company advanced development of its next-generation customer engagement and loyalty platforms, focusing on integrating card linked digital rewards into seamless, mobile-first experiences. The combined suite of solutions—comprising My Rewards' existing B2B loyalty and rewards programs, the Klevo consumer cashback card, Frankly Digital marketing services, and Fly Wallet's B2B Mastercard powered custom rewards programs positions MRI as a holistic provider of loyalty, rewards, and engagement technologies.

### Reinstatement Conditions

My Rewards' securities have remained suspended from quotation on the ASX since 2 October 2023. The suspension was initiated due to ASX's determination that MRI's financial condition, at the time, did not satisfy the requirements under Listing Rule 12.2. Following the Company's response to the ASX financial condition query, published on 30 October 2023, ASX advised that MRI would remain suspended until the disclaimer of audit opinions in its 2023 Annual Report was addressed, and compliance with ASX Listing Rules, including Listing Rule 12.2, was demonstrated to the ASX's satisfaction.

As announced on the 3<sup>rd</sup> of July, ASX confirmed that upon the satisfaction of the Reinstatement Conditions, it intends to reinstate MRI's securities to official quotation. ASX retains an absolute overarching discretion on this decision.

MRI is eligible for reinstatement to official quotation, subject to several conditions details of which can be found in the announcement.<sup>1</sup> Key conditions are listed below:

- A partially underwritten 1-for-2 entitlement offer to raise up to A\$3.98 million at \$0.009 per share.

---

<sup>1</sup> <https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02964061-6A1271570&v=4a466cc3f899e00730cfbfc5ab8940c41f474b6>

- Shareholder approval for a debt conversion proposal converting up to A\$1.9 million of liabilities into equity.
- Closing of both offers via a full-form prospectus under the Corporations Act. (The ASX has since agreed to a transaction specific prospectus to be lodged with ASIC)
- Confirmation of cleared funds received for all share issues.
- Demonstration of compliance with ASX Listing Rules 12.1 and 12.2, including working-capital sufficiency for at least 12 months.
- Submission of updated pro forma financial statements and commitments

The Company will shortly be announcing an Annual General Meeting and Entitlement offer to meet the required conditions.

### **Financial Overview**

An Appendix 4C Quarterly Cash Flow Report accompanies this announcement.

Key highlights include:

- Net cash from operating activities for the quarter ended 30 June 2025 was \$89,000.

### **About My Rewards International Limited (ASX: MRI)**

My Rewards International Limited is a global provider of customised subscription-based marketplaces, servicing both corporate clients and consumers. The Company's core solutions include loyalty technology platforms, rewards programs, customer experience enhancement, and digital marketing services.

**This announcement has been authorised for release by the board of directors of My Rewards International Limited.**

For enquiries:

**David Vinson**

Chairman

My Rewards International

[shareholders@myrewards.com.au](mailto:shareholders@myrewards.com.au)

## Appendix 4C

### Quarterly cash flow report for entities subject to Listing Rule 4.7B

#### Name of entity

My Rewards International Limited (ASX: MRI)

#### ABN

47 095 009 742

#### Quarter ended ("current quarter")

30 June 2025

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (12 months) \$A'000
<b>1. Cash flows from operating activities</b>		
1.1 Receipts from customers	1,459	2,341
1.2 Payments for		
(a) research and development		
(b) product manufacturing and operating costs	(943)	(1,647)
(c) advertising and marketing	(6)	(63)
(d) leased assets	(21)	(116)
(e) staff costs	(51)	(425)
(f) administration and corporate costs	(348)	(1,012)
1.3 Dividends received (see note 3)		
1.4 Interest received		
1.5 Interest and other costs of finance paid	(1)	(14)
1.6 Income taxes paid		
1.7 Government grants and tax incentives		
1.8 Other (provide details if material)		(2)
<b>1.9 Net cash from / (used in) operating activities</b>	<b>89</b>	<b>(938)</b>
<b>2. Cash flows from investing activities</b>		
2.1 Payments to acquire or for:		
(g) entities		
(h) businesses		
(i) property, plant and equipment		
(j) investments		
(k) intellectual property		
(l) other non-current assets		

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (12 months) \$A'000
2.2	Proceeds from disposal of:		
	(a) entities		
	(b) businesses		
	(c) property, plant and equipment		
	(d) investments		
	(e) intellectual property		
	(f) other non-current assets		
2.3	Cash flows from loans to other entities		
2.4	Dividends received (see note 3)		
2.5	Other (provide details if material)	433	433
<b>2.6</b>	<b>Net cash from / (used in) investing activities</b>	<b>433</b>	<b>433</b>

<b>3.</b>	<b>Cash flows from financing activities</b>		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	175	1,612
3.2	Proceeds from issue of convertible debt securities		
3.3	Proceeds from exercise of options		
3.4	Transaction costs related to issues of equity securities or convertible debt securities	(105)	(169)
3.5	Proceeds from borrowings	113	138
3.6	Repayment of borrowings	(3)	(388)
3.7	Transaction costs related to loans and borrowings		
3.8	Dividends paid		
3.9	Other (provide details if material)		
<b>3.10</b>	<b>Net cash from / (used in) financing activities</b>	<b>180</b>	<b>1,193</b>

<b>4.</b>	<b>Net increase / (decrease) in cash and cash equivalents for the period</b>		
4.1	Cash and cash equivalents at beginning of period	(52)	(38)
4.2	Net cash from / (used in) operating activities (item 1.9 above)	<b>89</b>	<b>(938)</b>
4.3	Net cash from / (used in) investing activities (item 2.6 above)	433	433

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (12 months) \$A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	180	1,193
4.5	Effect of movement in exchange rates on cash held	(5)	(5)
<b>4.6</b>	<b>Cash and cash equivalents at end of period</b>	<b>645</b>	<b>645</b>

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	645	(52)
5.2	Call deposits		
5.3	Bank overdrafts		
5.4	Other (provide details)		
<b>5.5</b>	<b>Cash and cash equivalents at end of quarter (should equal item 4.6 above)</b>	<b>645</b>	<b>(52)</b>

6.	Payments to related parties of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	-
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-
<i>Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.</i>		

7.	<b>Financing facilities</b>	<b>Total facility amount at quarter end \$A'000</b>	<b>Amount drawn at quarter end \$A'000</b>
	<i>Note: the term "facility" includes all forms of financing arrangements available to the entity. Add notes as necessary for an understanding of the sources of finance available to the entity.</i>		
7.1	Loan facilities	-	-
7.2	Credit standby arrangements	-	-
7.3	Other (please specify)	15,113	113
7.4	<b>Total financing facilities</b>	<b>15,113</b>	<b>113</b>
7.5	<b>Unused financing facilities available at quarter end</b>		15,000
7.6	Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		
	<p>On 27 February 2023, the Company entered into a put option facility with LDA Capital Limited for an amount of \$15 million. The term for this facility is 36 months expiring Feb 2026 unless extended by mutual agreement. The details of this facility can be found on the ASX announcement dated 27 February 2023.</p>		

8.	<b>Estimated cash available for future operating activities</b>	<b>\$A'000</b>
8.1	Net cash from / (used in) operating activities (item 1.9)	89
8.2	Cash and cash equivalents at quarter end (item 4.6)	645
8.3	Unused finance facilities available at quarter end (item 7.5)	15,000
8.4	Total available funding (item 8.2 + item 8.3)	15,758
8.5	<b>Estimated quarters of funding available (item 8.4 divided by item 8.1)</b>	117.06
	<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>	
8.6	If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
	8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
	Answer: N/A	
	8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
	Answer: N/A	
	8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?	
	Answer: N/A	
	<i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i>	

**Compliance statement**

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 31 July 2025

Authorised by: .....Board of Directors.....  
(Name of body or officer authorising release – see note 4)

**Notes**

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.